Publicacións nas que colabora con Rocio Gonzalez-Conejero Hilla (37)

2020

  1. Pilot study on the role of circulating mirnas for the improvement of the predictive ability of the 2mace score in patients with atrial fibrillation

    Journal of Clinical Medicine, Vol. 9, Núm. 11, pp. 1-11

2019

  1. Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals

    Clinical Pharmacology and Therapeutics, Vol. 105, Núm. 6, pp. 1477-1491

2018

  1. MiR-146a Regulates Neutrophil Extracellular Trap Formation That Predicts Adverse Cardiovascular Events in Patients with Atrial Fibrillation

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 38, Núm. 4, pp. 892-902

  2. MiR-146a deficiency in hematopoietic cells is not involved in the development of atherosclerosis

    PLoS ONE, Vol. 13, Núm. 6

  3. Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation

    European Journal of Clinical Investigation, Vol. 48, Núm. 6

2017

  1. Regulation of TFPIα expression by miR-27a/b-3p in human endothelial cells under normal conditions and in response to androgens

    Scientific Reports, Vol. 7

2016

  1. Genotype-guided therapy improves initial acenocoumarol dosing: Results from a prospective randomised study

    Thrombosis and Haemostasis, Vol. 115, Núm. 1, pp. 117-125

  2. MiRNA-based regulation of hemostatic factors through hepatic nuclear factor-4 alpha

    PLoS ONE, Vol. 11, Núm. 5

2014

  1. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment

    Pharmacogenomics, Vol. 15, Núm. 7, pp. 987-996

  2. Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation

    Thrombosis and Haemostasis, Vol. 112, Núm. 4, pp. 781-788

2013

  1. Creating a genotype-based dosing algorithm for acenocoumarol steady dose

    Thrombosis and Haemostasis, Vol. 109, Núm. 1, pp. 146-153

  2. Novel Associations of VKORC1 Variants with Higher Acenocoumarol Requirements

    PLoS ONE, Vol. 8, Núm. 5

2012

  1. miR-133a regulates Vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the Vitamin K cycle

    Molecular Medicine, Vol. 18, Núm. 11, pp. 1466-1472

2010

  1. Influence of the F12-4 C>T polymorphism on hemostatic tests

    Blood Coagulation and Fibrinolysis, Vol. 21, Núm. 7, pp. 632-639

  2. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements

    Journal of Thrombosis and Haemostasis, Vol. 8, Núm. 5, pp. 1012-1017

  3. Study of 18 functional hemostatic polymorphisms in mucocutaneous bleeding disorders

    Annals of Hematology, Vol. 89, Núm. 11, pp. 1147-1154

  4. Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction

    Thrombosis and Haemostasis

2009

  1. Antithrombin Cambridge ll (A384S) supports a role for antithrombin deficiency in arterial thrombosis

    Thrombosis and Haemostasis, Vol. 101, Núm. 3, pp. 483-486

  2. Implications of pharmacogenetics for oral anticoagulants metabolism

    Current Drug Metabolism, Vol. 10, Núm. 6, pp. 632-642

  3. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy

    Blood, Vol. 113, Núm. 20, pp. 4977-4979